cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action
Top Cited Papers
- 17 August 2010
- journal article
- review article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Pharmacological Reviews
- Vol. 62 (3), 525-563
- https://doi.org/10.1124/pr.110.002907
Abstract
To date, studies suggest that biological signaling by nitric oxide (NO) is primarily mediated by cGMP, which is synthesized by NO-activated guanylyl cyclases and broken down by cyclic nucleotide phosphodiesterases (PDEs). Effects of cGMP occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. cGMP binding activates PKG, which phosphorylates serines and threonines on many cellular proteins, frequently resulting in changes in activity or function, subcellular localization, or regulatory features. The proteins that are so modified by PKG commonly regulate calcium homeostasis, calcium sensitivity of cellular proteins, platelet activation and adhesion, smooth muscle contraction, cardiac function, gene expression, feedback of the NO-signaling pathway, and other processes. Current therapies that have successfully targeted the NO-signaling pathway include nitrovasodilators (nitroglycerin), PDE5 inhibitors [sildenafil (Viagra and Revatio), vardenafil (Levitra), and tadalafil (Cialis and Adcirca)] for treatment of a number of vascular diseases including angina pectoris, erectile dysfunction, and pulmonary hypertension; the PDE3 inhibitors [cilostazol (Pletal) and milrinone (Primacor)] are used for treatment of intermittent claudication and acute heart failure, respectively. Potential for use of these medications in the treatment of other maladies continues to emerge.Keywords
This publication has 508 references indexed in Scilit:
- Protein S-nitrosylation in health and disease: a current perspectiveTrends in Molecular Medicine, 2009
- Cyclic GMP specifically suppresses Type-Iα cGMP-dependent protein kinase expression by ubiquitinationCellular Signalling, 2009
- Regulation of inositol 1,4,5-trisphosphate-induced Ca2+ release by reversible phosphorylation and dephosphorylationBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2009
- A‐kinase anchoring proteins: From protein complexes to physiology and diseaseIUBMB Life, 2009
- Sildenafil Stops Progressive Chamber, Cellular, and Molecular Remodeling and Improves Calcium Handling and Function in Hearts With Pre-Existing Advanced Hypertrophy Caused by Pressure OverloadJournal of the American College of Cardiology, 2009
- Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytesCellular Signalling, 2008
- AKAP-Lbc Mobilizes a Cardiac Hypertrophy Signaling PathwayMolecular Cell, 2008
- Differential regulation of RhoA-mediated signaling by the TPα and TPβ isoforms of the human thromboxane A2 receptor: Independent modulation of TPα signaling by prostacyclin and nitric oxideCellular Signalling, 2008
- cGMP-dependent protein kinase anchoring by IRAG regulates its nuclear translocation and transcriptional activityCellular Signalling, 2008
- Homologous desensitization of signalling by the alpha (α) isoform of the human thromboxane A2 receptor: A specific role for nitric oxide signallingBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007